Diamyd Medical AB (publ) (STO:DMYD.B)
Sweden · Delayed Price · Currency is SEK 17.24
+0.86 (5.25%)
At close: Feb 9, 2026
Diamyd Medical AB Revenue
Diamyd Medical AB had revenue of 245.00K SEK in the quarter ending November 30, 2025, with 842.31% growth. This brings the company's revenue in the last twelve months to 349.00K, up 188.43% year-over-year. In the fiscal year ending August 31, 2025, Diamyd Medical AB had annual revenue of 130.00K.
Revenue (ttm)
349.00K
Revenue Growth
+188.43%
P/S Ratio
6,792.25
Revenue / Employee
8.51K
Employees
41
Market Cap
2.37B
Revenue Chart
Revenue History
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Aug 31, 2025 | 130.00K | - | - |
| Aug 31, 2024 | 130.00K | -416.00K | -76.19% |
| Aug 31, 2023 | 546.00K | 92.00K | 20.26% |
| Aug 31, 2022 | 454.00K | 201.00K | 79.45% |
| Aug 31, 2021 | 253.00K | -88.00K | -25.81% |
| Aug 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Aug 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
| Company Name | Revenue |
|---|---|
| Saniona AB | 743.21M |
| BioInvent International AB | 244.85M |
| Hansa Biopharma AB | 178.61M |
| Genovis AB (publ.) | 117.66M |
| Oncopeptides AB | 62.47M |
| Egetis Therapeutics AB | 55.40M |
| Vicore Pharma Holding AB | 8.50M |
| Xspray Pharma AB | 3.81M |
Diamyd Medical AB News
- 3 months ago - Diamyd Medical AB (publ) (DYMDF) Panel Discussion on Advances and Challenges in Type 1 Diabetes for World Diabetes Day Transcript - Seeking Alpha